EUCTR2006-001589-17-CZ进行中（未招募）不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injury
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 108
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age 18-65 years;
- •2. Comatose patients with severe TBI and a Glasgow Coma Score (GCS) 3-8 as initially assessed (eg, by the emergency physician) after resuscitation and hemodynamical stabilization but before intubation and/or sedation;
- •On arriving the hospital, the study physician should use his own judgment based on the report of the emergency doctor and the current status of the patient that the coma is due to trauma.
- •Patients who have a GCS>8 and/or are not comatose and/or are not comatose at the scene where the trauma occurred but deteriorate, eg, during transport to the hospital, may still be eligible for the study;
- •3. Blunt severe head trauma;
- •4. Hemodynamically stable (systolic blood pressure > 90 mmHg) after resuscitation/stabilization;
- •5. Start of treatment with study medication is feasible within 4.5 hours of onset of TBI (where onset of TBI is the time of impact. If the exact time of impact is not known, a conservative approach will be followed for the estimation of time of impact, ie, if an interval was provided for time of impact—eg, between 10:00 and 11:00 hours—the earlier end of that interval [10:00 hours] should be assumed as time of impact;
- •6. Informed consent obtained according to national and local legislation (see Section 9.7);
- •7. Negative urine pregnancy test in all female patients (as all patients are comatose and child bearing potential may not be ruled out in some women).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. TBI due to penetrating head injuries or gun shot wounds;
- •2. Any major spinal cord injury;
- •3. Initially bilateral non-reactive dilated pupils;
- •4. Major injury that requires/is expected to require >2500 mL of blood (> 5 blood units) within 12 hours of TBI;
- •Note: Patients requiring decompressive surgery may still be eligible for this study;
- •5. Known or CT scan evidence of previous major cerebral damage;
- •6. Coma due to other causes than TBI;
- •If information on the following exclusion criteria is available prior to randomization, these patients should be excluded, see Section 4.3.
- •7. Receiving an experimental drug within 4 weeks prior to current injury;
- •8. Known history of disability that may interfere with further evaluation;
- •9. Any severe concomitant disease that may either relevantly affect the safety of the patient, the efficacy of the drug (eg, psychiatric disorders such as but not limited to dementia, schizophrenia, mania, personality disorders), or the metabolism of the drug (eg, severe renal or hepatic disease);
- •10. Patient with known hypersensitivity to any CB;
- •11. Patients unlikely to be available for follow-up (eg, patients from abroad);
- •12. Patients unlikely to survive as determined by qualified study physicians before randomization;
- •13. Patients with known CB intake within 3 days prior to TBI.
研究者
相似试验
进行中（未招募）
不适用
A doubel-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-DEKeyNeurotek Pharmaceuticals AG108
进行中（未招募）
不适用
A double-blind, parallel-group, Phase IIa study to investigate the efficacy, safety and pharmacokinetics of two dose levels of KN 38-7271 versus placebo in comatose patients with severe traumatic brain injuryComatose patients with traumatic brain injury (TBI).EUCTR2006-001589-17-BEKeyNeurotek Pharmaceuticals AG108
招募中
2 期
A study to investigate improvement in physical function in SF-36 with Vericiguat compared with Placebo in participants with post-COVID-19 syndrome (PCS and PCS/CFS)2024-517713-33-00Charite Universitaetsmedizin Berlin KöR104
已完成
2 期
An Early Phase-II, Randomized, Double-blind, Study of TAS5315 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexaterheumatoid arthritisJPRN-jRCT2080223962Taiho Pharmaceutical Co., Ltd.90
进行中（未招募）
不适用
A Phase II, Randomised, Double-Blind Study to Compare the Safety and Efficacy of One Treatment Cycle of Clostridium Botulinum Type A Toxin (50 Units) When Reconstituted from Either a 125 Unit or a 500 Unit Presentation for the Treatment of Glabellar LinesModerate to severe vertical glabellar lines.MedDRA version: 9.1Level: LLTClassification code 10052609Term: Glabellar frown linesEUCTR2007-005958-23-DEIpsen Group, SCRAS Institut Henri Beaufour